Rxo (RXO) Payables (2021 - 2026)

Rxo (RXO) has 6 years of Payables data on file, last reported at $584.0 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 17.27% year-over-year to $584.0 million; the trailing twelve-month figure through Mar 2026 stood at $584.0 million (up 17.27% YoY), and the FY2025 full-year result was $539.0 million, down 5.11% from the prior year.
• Payables for Q1 2026 stood at $584.0 million, up from $539.0 million in the prior quarter.
• Across five years, Payables topped out at $584.0 million in Q1 2026 and bottomed at $372.0 million in Q1 2024.
• The 5-year median for Payables is $496.0 million (2023), against an average of $486.3 million.
• Peak annual rise in Payables reached 37.2% in 2024, while the deepest fall reached 25.0% in 2024.
• A 5-year view of Payables shows it stood at $501.0 million in 2022, then dropped by 17.37% to $414.0 million in 2023, then surged by 37.2% to $568.0 million in 2024, then retreated by 5.11% to $539.0 million in 2025, then increased by 8.35% to $584.0 million in 2026.
• The last three Payables figures came in at $584.0 million (Q1 2026), $539.0 million (Q4 2025), and $481.0 million (Q3 2025), per Business Quant data.

Peer Comparison